|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. National, State, and Urban Area Vaccination Coverage Levels Among Children Aged 19-35 Months -- United States, April 1994-March 1995The National Immunization Survey (NIS) is an ongoing survey to provide national, state, and selected urban area estimates of vaccination coverage levels among children aged 19-35 months. CDC implemented NIS in April 1994 as one element of the five-part Childhood Immunization Initiative (CII) (1), a national strategy to achieve and maintain high vaccination levels among children during the first 2 years of life; CII contains interim goals to the year 2000 national objectives (2). NIS collects quarterly data from all 50 states, the District of Columbia, and 27 urban areas considered to be at high risk for undervaccination. This report provides the results of national, state, and urban area vaccination coverage levels for April 1994-March 1995, which document the highest overall vaccination levels ever achieved for preschool-aged children in the United States, but a wide range (41 percentage points) between areas with the highest and lowest vaccination coverage levels. NIS uses a two-phase sample design: the first phase employs a quarterly random sample of telephone numbers for each survey area and includes administration of a screening questionnaire to respondents aged greater than or equal to 18 years to locate households with one or more children aged 19-35 months. Vaccination information is collected for age-eligible children. All respondents are asked to refer to written records; however, reports from recall also are accepted. During April 1994-March 1995, approximately 1.6 million telephone numbers were called, and 33,876 interviews were completed (an average of 434 interviews per area). The overall response rate for eligible households was 70% (range: 60%-85% among the 78 survey sites). In the second phase, vaccination information is requested from health-care providers of children in surveyed households. During 1994, households were excluded that used records indicating their children received all recommended doses of four specific vaccines. * All households identified in the first quarter of 1995 were included in the second phase. Based on exclusions, 27,108 (80%) children were eligible for the second phase; of these, vaccination information was obtained from providers for 11,609 (43%) children. The demographic characteristics and the reported vaccination histories were similar for children in households with and without provider information. Overall, for 54% of the children in the survey, either written records of having received all of the required doses for the four vaccines were available, or vaccination information based on provider records was available. The data obtained from provider records enabled improvements in the accuracy of the vaccination coverage estimates for the entire sample. Standard two-phase estimation procedures (3) were used to estimate vaccination coverage for each surveyed area. Estimates were adjusted using natality data to create a weighted sample representative of children aged 19-35 months in the United States; in addition, adjustments were made for non-response and for exclusion of households without a telephone because children in households without telephones are less likely to be vaccinated than children in households with a telephone (4; CDC, unpublished data, 1995). Based on NIS, among children born during May 1991-August 1993 and who were aged 19-35 months (median age: 27 months) at the time of the survey, estimated vaccination coverage was greater than 90% for three or more doses of diphtheria and tetanus toxoids and pertussis vaccine (DTP); coverage for three or more doses of poliovirus vaccine, one dose of measles-mumps- rubella vaccine (MMR), and three or more doses of Haemophilus influenzae type b vaccine (Hib) ranged from 84% to 90% (Table_1). Hepatitis B vaccine coverage was 42% and ranged from 24% for children aged 25-35 months to 58% for children aged 19-24 months. Estimated vaccination coverage was 75% (95% confidence interval {CI}=plus or minus 1.0%) for receipt of at least four doses of DTP, three doses of poliovirus vaccine, and one dose of MMR (4:3:1 series). When the series was expanded to include three doses of Hib (4:3:1:3 series), estimated coverage levels were 72% (95% CI=plus or minus 1.1%). The lower overall coverage for the 4:3:1 and 4:3:1:3 series compared with coverage for the individual vaccines was accounted for primarily by low coverage for the fourth dose of DTP (77%). State-specific estimated coverage levels for the 4:3:1 series ranged from 63% (95% CI=plus or minus 5.3%) to 87% (95% CI=plus or minus 4.1%), and for the 4:3:1:3 series from 59% (95% CI=plus or minus 5.3%) to 86% (95% CI=plus or minus 4.2%) (Table_2). Estimated coverage levels among selected large urban areas ranged from 52% (95% CI=plus or minus 8.2%) to 87% (95% CI=plus or minus 5.2%) for the 4:3:1 series, and from 46% (95% CI=plus or minus 8.0%) to 87% (95% CI=plus or minus 5.2%) for the 4:3:1:3 series (Table_3). To assess the validity of estimates from NIS, findings were compared with coverage estimates from the National Health Interview Survey (NHIS) (CDC, unpublished data, 1995), a national household survey of the U.S. civilian, noninstitutionalized population. During 1994, NHIS data had been supplemented with provider information in the same manner as in NIS. The estimated coverage levels in NIS of 75% for the 4:3:1 series and 72% for the 4:3:1:3 series were similar to those in NHIS (73% and 71%, respectively). Vaccine coverage levels for each vaccine (except for hepatitis B) were nearly identical (Table_1). Reported by: National Center for Health Statistics; Assessment Br, Data Management Div, National Immunization Program, CDC. Editorial NoteEditorial Note: The NIS data provide the first population-based state and urban area-specific estimates of vaccination coverage produced by a standard methodology for the United States. NIS permits monitoring of coverage levels of existing vaccines and tracking of the implementation of vaccination with new vaccines. Vaccination coverage estimates from the April 1994-March 1995 NIS and the 1994 NHIS are the highest ever recorded in the United States. In particular, findings from NIS indicate achievement of the 1996 CII goal for 90% coverage with three doses each of DTP and Hib, and the 90% coverage goals for polio and measles were nearly attained (5). Estimated coverage for hepatitis B, the vaccine most recently added to the pediatric schedule, was the lowest because, within the 19-35-month age group, many children were born before this vaccine was recommended (6). Estimated coverage increased with successive age cohorts born after the recommendation for hepatitis B was widely disseminated (Table_1). In addition, the NIS-based estimate of coverage for hepatitis B vaccine probably exceeds that from NHIS because NHIS assessed coverage from January through December 1994, when a higher proportion of children were born before promulgation of the recommendation for universal hepatitis B vaccination. In addition, NIS assessed coverage from April 1994 through March 1995, when all children surveyed were born after the recommendation went into effect. The Advisory Committee on Immunization Practices recently reaffirmed its recommendation for a fourth dose of DTP for all children aged 12-18 months (1). Recently completed field trials suggest that the efficacy of whole-cell vaccine can decrease substantially greater than 6 months after the third dose and underscore the need for boosting immunity with a fourth dose of DTP (7,8). Findings in this report indicate that coverage with four doses of DTP was the lowest of the four vaccines included in the combined series, emphasizing the importance of intensifying efforts to ensure timely administration of the fourth dose of DTP and the need for simultaneous administration with other vaccines recommended for children aged 12-18 months. One of the national health objectives for the year 2000 is to achieve series-complete coverage for the recommended vaccines among at least 90% of children aged 2 years (objective 20.11) (2). Series-specific coverage levels that include Hib (i.e., 4:3:1:3 series) are reported here. All children included in the survey were born after October 1990, when recommendations for universal Hib vaccination of infants became effective. Coverage levels varied substantially by state and large urban areas (e.g., a difference of 27 percentage points in 4:3:1:3 coverage between the states and 41 percentage points between the urban areas with the highest and lowest reported coverage levels). Although reasons for these differences have not been determined, these findings suggest that the national goals are achievable and that effective approaches should be adapted from the most successful areas. Efforts must be intensified to increase coverage among children in those areas with the lowest coverage. Publication of the state NIS data in August 1995 assisted in strengthening vaccination program activities at the state level in some areas with the lowest coverage (9). For example, in Michigan, related efforts have included creation of a new plan to address undervaccination; organization of meetings with health-care providers, community groups, and business leaders to discuss undervaccination; and conducting an immunization summit at which the Michigan Department of Public Health initiated a new statewide vaccination information campaign. In Missouri, the governor established as a priority the need to increase vaccination levels of children aged less than 2 years and established goals of increasing levels to 75% by 1996 and to 90% by 1997. CDC will continue to use data from NIS and NHIS to evaluate progress toward national vaccination goals and to stimulate further efforts to improve vaccination coverage. References
These vaccines were four doses of diphtheria and tetanus toxoids and pertussis vaccine, three doses of poliovirus vaccine, one dose of measles- mumps-rubella vaccine, and three doses of Haemophilus influenzae type b vaccine. +-------------------------------------------------------------------
------+
|
|
| Erratum: Vol. 45, No. 7
|
|
|
| SOURCE: MMWR 45(09);196 DATE: Mar 08, 1996
|
|
|
| In the report, "National, State, and Urban Area Vaccination
|
| Coverage Levels Among Children Aged 19-35 Months -- United
States, |
| April 1994-March 1995," on page 149 in Table_3 in the column
for |
| 4:3:1:3 series coverage, the percentage coverage for Chicago
should |
| be 55.
|
|
|
+-------------------------------------------------------------------
------+ TABLE 1. Vaccination coverage levels among children aged 19-35 months, by selected vaccines -- National Immunization Survey (NIS), United States, April 1994-March 1995 -------------------------------------------------------------------------------------- NHIS * NIS+ 1996 Year 2000 ---------------- ---------------------- Vaccine/Dose Goal Objective % (95% CI+) % (95% CI) -------------------------------------------------------------------------------------- DTP/DT & >=3 Doses 90% 90% 93 (+/- 1.4%) 94 (+/-0.6%) >=4 Doses -- 90% 75 (+/- 2.4%) 77 (+/-1.0%) Poliovirus >=3 Doses 90% 90% 83 (+/- 2.2%) 84 (+/-0.9%) Haemophilus influenzae type B >=3 Doses 90% 90% 89 (+/- 1.8%) 90 (+/-0.7%) MMR @ >=1 Dose 90% 90% 87 (+/- 1.8%) 89 (+/-0.8%) Hepatitis B >=3 Doses 70% 90% 26 (+/- 2.2%) 42 (+/-1.2%) 19-24 months 41 (+ 4.1%) 58 (+/-1.4%) 25-30 months 23 (+ 3.5%) 41 (+/-1.4%) 31-35 months 10 (+ 2.9%) 24 (+/-1.3%) Combined series 4 DTP/3 Polio/1 MMR ** -- 90% 73 (+/- 2.4%) 75 (+/-1.0%) 4 DTP/3 Polio/1 MMR/ 3 Hib ++ -- 90% 71 (+/- 2.4%) 72 (+/-1.1%) -------------------------------------------------------------------------------------- * 1994 National Health Interview Survey. + Confidence interval. & Diphtheria and tetanus toxoids and pertussis vaccine/Diphtheria and tetanus toxoids. @ Measles-mumps-rubella vaccine. ** Four doses of DTP/DT, three doses of poliovirus vaccine, and one dose of MMR. ++ Four doses of DTP/DT, three doses of poliovirus vaccine, one dose of MMR, and three doses of Hib. ====================================================================================== Return to top. Table_2 Note: To print large tables and graphs users may have to change their printer settings to landscape and use a small font size. TABLE 2. Estimated vaccination coverage with the 4:3:1 series * and 4:3:1:3 series +, by coverage level and state -- National Immunization Survey, United States, April 1995-March 1995 ==================================================================================================== 4:3:1 Series coverage 4:3:1:3 Series coverage Coverage level/ ----------------------- Coverage level/ --------------------------------- State % (95% CI &) State % (95% CI) ---------------------------------------------------------------------------------------------------- >=85% >=85% Connecticut 86 (+/-4.8%) Vermont 86 (+/-4.2%) Massachusetts 85 (+/-4.2%) 75%-84% Vermont 87 (+/-4.1%) Connecticut 84 (+/-5.2%) 75%-84% Delaware 79 (+/-5.8%) Arizona 77 (+/-4.3%) Florida 78 (+/-4.9%) Colorado 76 (+/-5.8%) Georgia 75 (+/-5.4%) Delaware 81 (+/-5.7%) Hawaii 80 (+/-5.6%) Florida 79 (+/-4.8%) Iowa 82 (+/-4.8%) Georgia 76 (+/-5.3%) Kansas 79 (+/-5.1%) Hawaii 84 (+/-5.1%) Kentucky 80 (+/-5.3%) Iowa 83 (+/-4.5%) Maine 80 (+/-5.1%) Kansas 82 (+/-4.8%) Maryland 77 (+/-4.8%) Kentucky 81 (+/-5.2%) Massachusetts 83 (+/-4.5%) Maine 83 (+/-4.9%) Minnesota 77 (+/-5.3%) Maryland 79 (+/-4.6%) Mississippi 80 (+/-5.5%) Minnesota 78 (+/-5.2%) New Hampshire 82 (+/-5.2%) Mississippi 80 (+/-5.5%) New York 75 (+/-4.6%) New Hampshire 84 (+/-5.0%) North Carolina 79 (+/-5.6%) New York 76 (+/-4.5%) North Dakota 80 (+/-4.5%) North Carolina 83 (+/-5.3%) Pennsylvania 76 (+/-4.6%) North Dakota 82 (+/-4.4%) Rhode Island 81 (+/-5.2%) Pennsylvania 78 (+/-4.4%) South Carolina 79 (+/-5.3%) Rhode Island 83 (+/-5.0%) Virginia 77 (+/-5.8%) South Carolina 81 (+/-5.3%) Wyoming 76 (+/-5.4%) South Dakota 76 (+/-5.6%) 65%-74% Virginia 78 (+/-5.8%) Alabama 73 (+/-5.3%) Washington 75 (+/-4.2%) Alaska 68 (+/-6.2%) Wisconsin 76 (+/-4.4%) Arizona 74 (+/-4.5%) Wyoming 79 (+/-5.2%) Arkansas 66 (+/-6.1%) 65%-74% California 70 (+/-4.6%) Alabama 74 (+/-5.2%) Colorado 73 (+/-6.1%) Alaska 72 (+/-6.1%) Idaho 65 (+/-6.3%) Arkansas 69 (+/-6.0%) Indiana 70 (+/-5.1%) California 73 (+/-4.5%) Louisiana 72 (+/-5.4%) Idaho 66 (+/-6.3%) Missouri 66 (+/-6.5%) Illinois 69 (+/-5.1%) Montana 71 (+/-5.7%) Indiana 72 (+/-5.0%) Nebraska 67 (+/-5.9%) Louisiana 74 (+/-5.3%) Nevada 65 (+/-6.6%) Missouri 67 (+/-6.5%) New Jersey 69 (+/-6.0%) Montana 72 (+/-5.7%) New Mexico 70 (+/-6.5%) Nebraska 72 (+/-5.7%) Ohio 73 (+/-4.6%) Nevada 68 (+/-6.5%) Oklahoma 70 (+/-6.7%) New Jersey 70 (+/-5.9%) Oregon 65 (+/-6.3%) New Mexico 73 (+/-6.2%) South Dakota 74 (+/-5.7%) Ohio 74 (+/-4.6%) Tennessee 70 (+/-4.3%) Oklahoma 73 (+/-6.6%) Texas 68 (+/-3.9%) Oregon 67 (+/-6.2%) Utah 67 (+/-4.9%) Tennessee 73 (+/-4.2%) Washington 73 (+/-4.3%) Texas 71 (+/-3.8%) West Virginia 68 (+/-6.3%) Utah 70 (+/-4.8%) Wisconsin 74 (+/-4.4%) West Virginia 69 (+/-6.3%) <65% <65% Illinois 64 (+/-5.2%) Michigan 63 (+/-5.3%) Michigan 59 (+/-5.3%) Total 75 (+/-1.0%) Total 72 (+/-1.1%) ---------------------------------------------------------------------------------------------------- * Four doses of diphtheria and tetanus toxoids and pertussis vaccine/Diphtheria and tetanus toxoids (DTP/DT), three doses of poliovirus vaccine, and one dose of measles-mumps-rubella vaccine (MMR). + Four doses of DTP/DT, three doses of poliovirus vaccine, one dose of MMR, and three doses of Haemophilus influenzae type B vaccine. & Confidence interval. ==================================================================================================== Return to top. Table_3 Note: To print large tables and graphs users may have to change their printer settings to landscape and use a small font size. TABLE 3. Estimated vaccination coverage with the 4:3:1 series * and the 4:3:1:3 series + for selected metropolitan areas -- National Immunization Survey, United States, April 1994-March 1995 ======================================================================================================= 4:3:1 Series coverage 4:3:1:3 Series coverage Coverage level/ ------------------------ Coverage level/ --------------------------------- Area % (95% CI&) Area % (95% CI) ------------------------------------------------------------------------------------------------------- >=85% >=85% Boston 87 (+/- 5.2%) Boston 87 (+/- 5.2%) Santa Clara Co., Calif. 85 (+/- 4.9%) 75%-84% 75%-84% Baltimore 77 (+/- 6.1%) Baltimore 80 (+/- 5.8%) Cuyahoga Co., Ohio 82 (+/- 5.5%) Cuyahoga Co., Ohio 84 (+/- 5.3%) El Paso Co., Tex. 79 (+/- 5.4%) Dade Co., Fla. 77 (+/- 6.4%) Fulton/DeKalb cos., Ga. 75 (+/- 6.9%) El Paso Co., Tex. 82 (+/- 5.1%) Jefferson Co., Ala. 75 (+/- 6.3%) Fulton/DeKalb cos., Ga. 77 (+/- 6.7%) Marion Co., Ind. 78 (+/- 6.1%) Jefferson Co., Ala. 78 (+/- 6.0%) Milwaukee Co., Wis. 77 (+/- 6.0%) Kings Co., Wash. 78 (+/- 5.3%) New York City 75 (+/- 6.5%) Maricopa Co., Ariz. 77 (+/- 6.1%) Santa Clara Co., Calif. 80 (+/- 5.6%) Marion Co., Ind. 81 (+/- 5.8%) 65%-74% Milwaukee Co., Wis. 80 (+/- 5.7%) Dade Co., Fla. 74 (+/- 6.6%) New York City 76 (+/- 6.5%) Dallas Co., Tex. 66 (+/- 7.0%) 65%-74% Davidson Co., Tenn. 67 (+/- 6.4%) Bexar Co., Tex. 67 (+/- 6.5%) District of Columbia 67 (+/- 7.3%) Dallas Co., Tex. 71 (+/- 6.6%) Duval Co., Fla. 71 (+/- 6.2%) Davidson Co., Tenn. 69 (+/- 6.3%) Franklin Co., Ohio 70 (+/- 6.8%) District of Columbia 72 (+/- 7.0%) Kings Co., Wash. 74 (+/- 5.6%) Duval Co., Fla. 74 (+/- 6.0%) Los Angeles Co., Calif. 68 (+/- 7.7%) Franklin Co., Ohio 71 (+/- 6.8%) Maricopa Co., Ariz. 74 (+/- 6.3%) Los Angeles Co., Calif. 73 (+/- 7.5%) Orleans Parish, La. 66 (+/- 7.8%) Orleans Parish, La. 67 (+/- 7.8%) Philadelphia Co., Pa. 69 (+/- 7.4%) Philadelphia Co., Pa. 71 (+/- 7.3%) San Diego, Co., Calif. 72 (+/- 5.8%) San Diego Co., Calif. 74 (+/- 5.8%) Shelby Co., Tenn. 71 (+/- 7.0%) Shelby Co., Tenn. 73 (+/- 6.9%) <65% <65% Bexar Co., Tex. 64 (+/- 6.6%) Chicago 61 (+/- 8.7%) Chicago 61 (+/- 8.7%) Detroit 52 (+/- 8.2%) Detroit 46 (+/- 8.0%) Houston 62 (+/- 8.1%) Houston 58 (+/- 8.0%) Newark, N.J. 62 (+/-10.0%) Newark, N.J. 55 (+/-10.1%) ------------------------------------------------------------------------------------------------------- * Four doses of diphtheria and tetanus toxoids and pertussis vaccine/Diphtheria and tetanus toxoids (DTP/DT), three doses of poliovirus vaccine, and one dose of measles-mumps-rubella vaccine (MMR). + Four doses of DTP, three doses of poliovirus vaccine, one dose of MMR, and three doses of Haemophilus influenzae type B vaccine. & Confidence interval. ======================================================================================================= Return to top. Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 09/19/98 |
|||||||||
This page last reviewed 5/2/01
|